FCER2 and B-cell chronic lymphocytic leukemia: Currently, Lumiliximab – a chimeric macaque and human anti-CD23 monoclonal antibody – is considered as immunomodulator and is in clinical trials for the treatment of patients with chronic lymphocytic leukemia [79].